{ "items" : [
    { "id" : "http://dbpedia.org/resource/Pertuzumab"
      "properties" : {
        "http://www.w3.org/2000/01/rdf-schema#comment" : [ "Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody marketed by Genentech for the treatment of HER2-positive breast cancer, in combination with trastuzumab and docetaxel. The first of its class in a line of agents called \"HER dimerization inhibitors\".  By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth." ] ,
        "http://xmlns.com/foaf/0.1/depiction" : [ "http://commons.wikimedia.org/wiki/Special:FilePath/Pertuzumab-HER2_complex_1S78.png" ] ,
        "http://dbpedia.org/ontology/atcPrefix" : [ "L01" ] ,
        "http://dbpedia.org/ontology/atcSuffix" : [ "XC13" ] ,
        "http://dbpedia.org/ontology/casNumber" : [ "380610-27-5" ] ,
        "http://dbpedia.org/ontology/fdaUniiCode" : [ "K16AIQ8CTM" ] ,
        "http://dbpedia.org/ontology/thumbnail" : [ "http://commons.wikimedia.org/wiki/Special:FilePath/Pertuzumab-HER2_complex_1S78.png?width=300"] } } }
